FMP
aTyr Pharma, Inc. Shares Reached The Highest Level Since 2018
Sep 14, 2021 6:20 PM - Davit Kirakosyan(Last modified: Dec 19, 2023 5:49 PM)
Image credit: FMP
aTyr Pharma, Inc. (NASDAQ:LIFE) shares were trading at the highest level since 2018, hitting the daily high of $12.97 today morning.
The reason is that the company presented top-line data from its Phase 1b/2a double-blind, placebo-controlled clinical trial of ATYR1923 in 37 patients with pulmonary sarcoidosis. The data surpassed the expectations, demonstrating a dose dependent improvement in such diverse efficacy measurements as steroid sparing (reduction), Forced Vital Capacity (FVC), clinical/QOL measurements like dyspnea, cough, etc., and inflammatory biomarker reductions; all this with little change in the safety profile of the drug.
Other Blogs
Oct 31, 2023 8:03 AM - Parth Sanghvi
FCFF vs FCFE: What's the Difference?
Free cash flow to the firm (FCFF) and free cash flow to equity (FCFE) are two of the most important metrics used in financial modeling. Both metrics measure the amount of cash that is available to a company's shareholders and creditors, but there is a key difference between the two. FCFF measures...
Nov 25, 2023 6:39 AM - Parth Sanghvi
DCF Valuation vs. Comparable Companies Analysis: Choosing the Right Valuation Method
Choosing the Right Valuation Method: DCF vs. Comparable Companies Analysis Introduction: Valuation methods play a pivotal role in determining the fair value of a company, aiding investors in making informed investment decisions. Two commonly used methods, DCF Valuation and Comparable Companies A...
Dec 23, 2023 2:19 AM - Parth Sanghvi
Understanding the Limitations of DCF Analysis: A Guide to Overcoming Challenges
Introduction: Discounted Cash Flow (DCF) analysis stands as a cornerstone in valuing investments, yet its efficacy is contingent upon various assumptions and methodologies. While a powerful tool, DCF analysis comes with inherent limitations and challenges that investors must acknowledge to make i...
